New Drug Approvals Archive - February 2012
Get news by email or subscribe to our news feeds.
February 2012
| February 2 |
Janumet (metformin and sitagliptin)
New Formulation Approved: February 2, 2012
Janumet (metformin and sitagliptin) FDA Approval History |
| February 7 |
Vyvanse (lisdexamfetamine dimesylate)
New Indication Approved: January 31, 2012
Vyvanse (lisdexamfetamine dimesylate) FDA Approval History |
| February 7 |
Sklice (ivermectin) Lotion Date of Approval: February 7, 2012
Company: Sanofi Pasteur Inc.
Treatment for: Lice
Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in patients 6 months of age and older. Sklice (ivermectin) FDA Approval History |
| February 7 |
Mitosol (mitomycin) Ophthalmic Solution Date of Approval: February 7, 2012
Company: Mobius Therapeutics, LLC
Treatment for: Glaucoma Surgery
Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. Mitosol (mitomycin) FDA Approval History |
| February 10 |
Zioptan (tafluprost) Ophthalmic Solution - formerly SaflutanDate of Approval: February 10, 2012
Company: Merck & Co., Inc.
Treatment for: Glaucoma (Open Angle), Intraocular Hypertension
Zioptan (tafluprost ophthalmic solution) is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Zioptan (tafluprost) FDA Approval History |
| February 14 |
Testosterone Gel (testosterone) Topical Gel - formerly Bio-T-GelDate of Approval: February 14, 2012
Company: ANI Pharmaceuticals, Inc.
Treatment for: Hypogonadism -- Male
Testosterone gel is a once-daily transdermal testosterone gel for the treatment of male hypogonadism or low
testosterone levels. Testosterone Gel (testosterone) FDA Approval History |
| February 17 |
Korlym (mifepristone) Tablets Date of Approval: February 17, 2012
Company: Corcept Therapeutics
Treatment for: Cushing's Syndrome
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance. Korlym (mifepristone) FDA Approval History |
| February 29 |
Angeliq (drospirenone and estradiol)
New Formulation Approved: February 29, 2012
Angeliq (drospirenone and estradiol) FDA Approval History |
New Drug Approvals Archive
2016
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2015
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2014
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2013
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2012
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2011
January,
February,
March,
April,
May,
June,
July,
August,
October,
November,
December2010
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2009
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2008
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2007
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2006
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2005
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2004
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2003
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December
